EUVIMEDEUVIMED entdecken
Crossref

EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS

Yuanbao Xie, Yu Chen, Jingjing Wu, Xinyue Yuan, xianghui Duan, Fei Liu, MING HU

Value in Health · 2026-06 · 29 (6) · S152

DOI: 10.1016/j.jval.2026.03.767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Yuanbao Xie und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Xie, Y., Chen, Y., Wu, J., Yuan, X., Duan, X., Liu, F., & HU, M. (2026). EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS. Value in Health, 29(6), S152. https://doi.org/10.1016/j.jval.2026.03.767

Vancouver

Xie Y, Chen Y, Wu J, Yuan X, Duan X, Liu F, et al. EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS. Value in Health. 2026;29(6):S152. doi:10.1016/j.jval.2026.03.767

BibTeX
@article{Xie2026,
  author = {Xie, Yuanbao and Chen, Yu and Wu, Jingjing and Yuan, Xinyue and Duan, xianghui and Liu, Fei and HU, MING},
  title = {EE474 BIREOCICLIB PLUS FULVESTRANT FOR HR+/HER2- ADVANCED OR METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S152},
  doi = {10.1016/j.jval.2026.03.767}
}
Kostenlos starten →